Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73% Market Closed
Market Cap: 457.1m GBX

EV/EBIT
Enterprise Value to EBIT

-357.7
Current
-2.1
Median
16.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-357.7
=
Enterprise Value
6.2B GBX
/
EBIT
-23.3m USD
EBIT Growth EV/EBIT to Growth
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average EV/EBIT: 1 870.6
Negative Multiple: -357.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.8
32%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.3
13%
1.4
CH
Roche Holding AG
SIX:ROG
10.4
6%
1.7
UK
AstraZeneca PLC
LSE:AZN
168.2
23%
7.3
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
14%
0.7
US
Merck & Co Inc
NYSE:MRK
9.5
10%
1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
16.5
2-Years Forward
EV/EBIT
0.9
3-Years Forward
EV/EBIT
0.6